Bender RG, Sirota SB, Swetschinski LR, Dominguez RMV, Novotney A, Wool EE, et al. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the global burden of Disease Study 2021. Lancet Infect Dis. 2024;24(9):974–1002.

Article  Google Scholar 

Volling C, Hassan K, Mazzulli T, Green K, Al-Den A, Hunter P, et al. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis. 2014;14:665.

Article  PubMed  PubMed Central  Google Scholar 

Jiang MY, Duan YP, Tong XL, Huang QR, Jia MM, Yang WZ, et al. Clinical manifestations of respiratory syncytial virus infection and the risk of wheezing and recurrent wheezing illness: a systematic review and meta-analysis. World J Pediatr. 2023;19(11):1030–40.

Article  PubMed  PubMed Central  Google Scholar 

Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64.

Article  PubMed  PubMed Central  Google Scholar 

Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al. Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries. Open Forum Infect Dis. 2023;10(11):ofad513.

Article  PubMed  PubMed Central  Google Scholar 

Nguyen-Van-Tam JS, O’Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev. 2022;31(166):220105.

Article  PubMed  PubMed Central  Google Scholar 

Savic M, Penders Y, Shi T, Branche A, Pirçon JY. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2023;17(1):e13031.

Article  CAS  PubMed  Google Scholar 

Rios-Guzman E, Simons LM, Dean TJ, Agnes F, Pawlowski A, Alisoltanidehkordi A, et al. Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic. Nat Commun. 2024;15(1):3374.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mejias A, Rodríguez-Fernández R, Oliva S, Peeples ME, Ramilo O. The journey to a respiratory syncytial virus vaccine. Ann Allergy Asthma Immunol. 2020;125(1):36–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

GSK. Medicines and Healthcare products Regulatory Agency authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults. 2023. https://www.gsk.com/en-gb/media/press-releases/medicines-and-healthcare-products-regulatory-agency-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/#:~:text=The%20MHRA%20has%20authorised%20Arexvy,aged%2060%20years%20and%20older.%26;text=It%20is%20also%20approved%20in,European%20Economic%20Area%20(EEA)*. Accessed 21 Aug 2024.

Pfizer. Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults. 2024. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-full-season-two. Accessed 21 Aug 2024.

Moderna, Moderna Receives, U.S. FDA Approval for RSV Vaccine mRESVIA®. 2024. https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx. Accessed 21 Aug 2024.

GSK. US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50–59 at increased risk. 2024. https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-expanded-age-indication-for-gsk-s-arexvy-the-first-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/. Accessed 21 Aug 2024.

Pfizer., U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease. 2024. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-rsv-vaccine-abrysvor-adults-aged-18. Accessed 06 Jan 2025.

Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–59.

Article  CAS  PubMed  Google Scholar 

Kurai D, Song J, Huang YC, Jie Z, Atanasov P, Jiang X, et al. Targeted literature review of the burden of respiratory syncytial infection among high-risk and elderly patients in Asia Pacific region. Infect Dis Ther. 2023;12(3):807–28.

Article  PubMed  PubMed Central  Google Scholar 

Kurai D, Saraya T, Ishii H, Takizawa H. Virus-induced exacerbations in asthma and COPD. Front Microbiol. 2013;4:293.

Article  PubMed  PubMed Central  Google Scholar 

Zheng XY, Xu YJ, Guan WJ, Lin LF. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol. 2018;163(4):845–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feddema J, Claassen E. Prevalence of viral respiratory infections amongst asthmatics: results of a meta-regression analysis. Respir Med. 2020;173:106020.

Article  CAS  PubMed  Google Scholar 

Zwaans WAR, Mallia P, van Winden MEC, Rohde GGU. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease—a systematic review. J Clin Virol. 2014;61(2):181–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wiseman DJ, Thwaites RS, Ritchie AI, Finney L, Macleod M, Kamal F, et al. RSV-related community COPD exacerbations and novel diagnostics: a binational prospective cohort study. Am J Respir Crit Care Med. 2024;210(8):994–1001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261–9.

Article  PubMed  Google Scholar 

Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;366:l5021.

Article  PubMed  Google Scholar 

Ackerson B, Tseng HF, Sy LS, Solano Z, Slezak J, Luo Y, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197–203.

Article  CAS  PubMed  Google Scholar 

Branche AR, Saiman L, Walsh EE, Falsey AR, Jia H, Barrett A, et al. Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. Influenza Other Respir Viruses. 2022;16(6):1151–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilkinson TMA, Donaldson GC, Johnston SL, Openshaw PJM, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(8):871–6.

Article  PubMed  Google Scholar 

Surie D, Yuengling KA, DeCuir J, Zhu Y, Lauring AS, Gaglani M, et al. Severity of respiratory syncytial virus vs COVID-19 and influenza among hospitalized US adults. JAMA Netw Open. 2024;7(4):e244954.

Article  PubMed  PubMed Central  Google Scholar 

Yuengling K, Surie D, DeCuir J, Zhu Y, Gaglani M, Ginde AA et al. 1108. Severity of illness among adults hospitalized with respiratory syncytial virus compared with COVID-19 and influenza—IVY Network, 25 Hospitals, 20 US States, January 31, 2022–April 11, 2023. Open Forum Infect Dis. 2023;10(Supplement_2):ofad500.081.

Begley KM, Monto AS, Lamerato LE, Malani AN, Lauring AS, Talbot HK, et al. Prevalence and clinical outcomes of respiratory syncytial virus vs influenza in adults hospitalized with acute respiratory illness from a prospective multicenter study. Clin Infect Dis. 2023;76(11):1980–8.

Article  PubMed  PubMed Central  Google Scholar 

Ciemins EL, Gillen A, Tallam M. RSV: a vaccine is coming, time to educate providers. Vaccine. 2023;41(32):4636–8.

Article  PubMed  Google Scholar 

Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H, RESCEU Investigators. Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: a systematic review and meta-analysis. J Infect Dis. 2022;226(Supplement1):S17–21.

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central